Investor Presentation via Investor Meet Company

Venture Life Group PLC

24 September 2026

 

24 September 2026

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Group")

Investor Presentation via Investor Meet Company

Venture Life (AIM: VLG) is pleased to announce that Jerry Randall (CEO), Daniel Wells (CFO) and Kate Bache (Chief Innovation & Marketing Officer) will provide a live presentation relating to the Final Results for the 17-month period ended 31 May 2026 via Investor Meet Company on 01 October 2026, 11:00 BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 30 September 2026, 09:00 BST, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Venture Life Group plc via:

https://www.investormeetcompany.com/venture-life-group-plc/register-investor

Investors who already follow Venture Life Group plc on the Investor Meet Company platform will automatically be invited.

For further information, please contact:

Venture Life Group PLC                                                                                                    [phone]

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

Cavendish Capital Markets Limited (Nomad and Broker)                                             [phone] 

Stephen Keys/George Lawson (Corporate Finance)

Michael Johnson (Sales) 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, the Health & Her/Him product ranges supporting the hormonal lifecycle, FemiClear products addressing a range of common gynaecological conditions, plus the Curoxen brand providing infection prevention solutions for wounds and mouth sores.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally. In the UK,  Ireland and the USA these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

 

END